<DOC>
	<DOCNO>NCT01545284</DOCNO>
	<brief_summary>This pilot , phase II , 24-week study recruit total 10 patient evaluate efficacy safety acitretin patient severe chronic hand dermatitis .</brief_summary>
	<brief_title>Pilot Study Use Acitretin Treatment Severe Chronic Hand Dermatitis</brief_title>
	<detailed_description>Patients receive acitretin daily maximum 24 week . Patients reach Physician Global Assessment ( PGA ) clear almost clear week 12 end study . Patients reach PGA clear almost clear week 12 continue treatment week 24 . The start dose 10mg/day , well tolerate , increase first 4 week maximum 30 mg/day .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<criteria>Men postmenopausal surgically sterile woman , 18 year age old time consent Has stable chronic hand dermatitis least 6 month Has chronic hand dermatitis PGA severe Day 0 Unless vasectomize least 6 month clinically diagnose infertile , male patient female partner childbearing potential , patient patient 's partner willing use effective contraceptive method least 30 day screen 2 year study . Male patient father child donate sperm study 2 year last treatment . Effective contraceptive method : Barrier method condom , sponge diaphragm combine spermicide foam , gel cream Female partner : Hormonal contraception ( oral , intramuscular , implant transdermal ) include DepoProvera , Evra Nuvaring . Oral contraceptive must take stable dose least 90 day study start Female partner : Intrauterine device ( IUD ) Female patient negative serum pregnancy test within 14 day Day 0 Capable give informed consent consent must obtain prior study related procedure . Female childbearing potential , pregnant lactating Has skin disease could impair his/her safety study interfere evaluation result Has know allergy acitretin , retinoids vitamin A derivates , component study product Has use acitretin within 24 week Day 0 Has use systemic retinoid ( include alitretinoin ) within 6 month Day 0 Has use tetracycline vitamin supplement contain vitamin A within 4 week Day 0 Has use methotrexate within 6 month Day 0 Has use systemic therapy ( e.g . corticosteroid , immunosuppressant phototherapy ) within four week Day 0 . Inhaled corticosteroid stable medical condition allow Has use topical treatment dermatitis ( e.g . retinoids , corticosteroid , tacrolimus , pimecrolimus ) hand within 14 day Day 0 . If patient use topical treatment dermatitis area body , must apply glove . Has use investigational agent within 30 day prior Day 0 , within 5 halflives investigational agent prior day 0 ( whichever longer ) Has history alcoholism drug abuse within 12 month prior Day 0 Is plan donate blood within 2 year end study Clinically significant increase hepatic enzyme , cholesterol triglyceride screen would , opinion investigator , put patient risk he/she receive acitretin Diagnosis symptom inflammatory bowel disease screen baseline Has unstable serious medical condition define investigator presence significant medical condition , include severe renal impairment , might cause study detrimental patient Diagnosis symptom active depression , include depression currently control medication , screen baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>chronic hand dermatitis</keyword>
	<keyword>acitretin</keyword>
	<keyword>PGA</keyword>
</DOC>